{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:06:54Z","timestamp":1792508814846,"version":"4.5.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,14]]},"DOI":"10.1182\/bloodadvances.2021006934","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T23:01:17Z","timestamp":1646348477000},"page":"3339-3342","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6165-2617","authenticated-orcid":false,"given":"Mengyang","family":"Di","sequence":"first","affiliation":[{"name":"1Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT;"},{"name":"2Yale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4736-4330","authenticated-orcid":false,"given":"Can","family":"Cui","sequence":"additional","affiliation":[{"name":"3Department of Immunobiology, Yale University School of Medicine, New Haven, CT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalin K.","family":"Kothari","sequence":"additional","affiliation":[{"name":"1Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"1Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT;"},{"name":"2Yale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-778X","authenticated-orcid":false,"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[{"name":"1Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT;"},{"name":"2Yale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Neparidze","sequence":"additional","affiliation":[{"name":"1Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT;"},{"name":"2Yale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-2944","authenticated-orcid":false,"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[{"name":"1Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT;"},{"name":"2Yale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[{"name":"2Yale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT;"},{"name":"4Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Ma","sequence":"additional","affiliation":[{"name":"2Yale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT;"},{"name":"4Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-6475","authenticated-orcid":false,"given":"Scott F.","family":"Huntington","sequence":"additional","affiliation":[{"name":"1Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT;"},{"name":"2Yale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"issue":"19","key":"2022060315235449300_B1","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood."},{"issue":"6","key":"2022060315235449300_B2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"2022060315235449300_B3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canep.2018.12.002","article-title":"Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995-2013: findings from Texas and national SEER areas","volume":"58","author":"Fu","year":"2019","journal-title":"Cancer Epidemiol."},{"issue":"22","key":"2022060315235449300_B4","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and\u00a0management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022060315235449300_B5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol."},{"issue":"11","key":"2022060315235449300_B6","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/ajh.26306","article-title":"Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era","volume":"96","author":"Karmali","year":"2021","journal-title":"Am J Hematol."},{"key":"2022060315235449300_B7","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2021.39.15_suppl.7504","article-title":"Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in U.S. routine clinical practice","volume":"39","author":"Martin","year":"2021","journal-title":"J Clin Oncol."},{"issue":"23","key":"2022060315235449300_B8","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2021004765","article-title":"Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy","volume":"5","author":"Bond","year":"2021","journal-title":"Blood Adv."},{"issue":"6","key":"2022060315235449300_B9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med."},{"issue":"11","key":"2022060315235449300_B10","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia."},{"key":"2022060315235449300_B11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2018-99-117956","article-title":"Safety and activity of the investigational Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma from a phase 2 trial","volume":"132","author":"Song","year":"2018","journal-title":"Blood."},{"key":"2022060315235449300_B12","author":"National Cancer Institue"},{"issue":"6","key":"2022060315235449300_B13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"issue":"5","key":"2022060315235449300_B14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","article-title":"Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"25","author":"Dietrich","year":"2014","journal-title":"Ann Oncol."},{"issue":"12","key":"2022060315235449300_B15","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol."},{"issue":"9873","key":"2022060315235449300_B16","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet."},{"issue":"19","key":"2022060315235449300_B17","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med."},{"issue":"29","key":"2022060315235449300_B18","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022060315235449300_B19","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med."},{"issue":"6","key":"2022060315235449300_B20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/11\/3339\/1899982\/advancesadv2021006934.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/11\/3339\/1899982\/advancesadv2021006934.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T15:24:34Z","timestamp":1654269874000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/11\/3339\/484266\/Survival-of-mantle-cell-lymphoma-in-the-era-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,6,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006934","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]}}}